Evidence map›Paper›PMID 32693779›Full record

ArticleBMC cancer2020

Clinical characteristics and prognosis of anal squamous cell carcinoma: a retrospective audit of 144 patients from 11 cancer hospitals in southern China.

Yong Lu, Xiaohao Wang, Peiyang Li, Tao Zhang, Jiaming Zhou, Yufeng Ren, Yi Ding, Haihua Peng, Qichun Wei, Kaiyun You and 6 more

Abstract readMulticenter Study
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Factors Influencing Outcomes and Survival in Anal Cancer.Current oncology (Toronto, Ont.) · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yong LuSchool of Public Health, Sun Yat-sen University, Guangzhou, 510080, China.
Xiaohao WangSun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510080, China.
Peiyang LiSchool of Public Health, Sun Yat-sen University, Guangzhou, 510080, China.
Tao ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Jiaming ZhouThe Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, China.
Yufeng RenThe First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Yi DingDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Haihua PengDepartment of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510075, China.
Qichun WeiDepartment of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Kaiyun YouDepartment of Radiation Oncology, Sun Yat-sen Memorial Hospital, Guangzhou, 510120, China.
Jason J OngCentral Clinical School, Monash University, Melbourne, Victoria, 3800, Australia.
Christopher K FairleyCentral Clinical School, Monash University, Melbourne, Victoria, 3800, Australia.
Andrew E GrulichKirby Institute, University of New South Wales, Sydney, 2052, Australia.
Meijin HuangThe Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, China. huangmj@mail.sysu.edu.cn.
Yuanhong GaoSun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510080, China. gaoyh@sysucc.org.cn.
Huachun ZouSchool of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, 518107, China. zouhuachun@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0002-8161-7576

Funding

Australian National Health and Medical Research Council Early Career Fellowship APP1092621Guangdong Natural Science Funds for Distinguished Young Scholar, China 2015A030306015Guangdong Program for Support of Top-notch Young Professionals, China 2015TQ01R279Sanming Project of Medicine in Shenzhen, China SZSM201811071The Fund of National Natural Science Foundation of China 81172152The Fund of National Natural Science Foundation of China 81572952The Fund of National Natural Science Foundation of China 81672987The Fund of National Natural Science Foundation of China 81872470
6 · The paper itself

Abstract

backgroundThe incidence of anal squamous cell carcinoma (SCC) has been steadily growing globally in the past decade. Clinical data on anal SCC from China are rare. We conducted this study to describe the clinical and epidemiological characteristics of anal SCC in China and explore prognostic factors of outcomes among patients with anal SCC.

methodsWe audited demographic characteristics, relevant symptoms, risk factors, treatment modalities and outcomes for patients diagnosed with anal SCC at 11 medical institutions in China between January 2007 and July 2018.

resultsA total of 144 patients (109 females) were diagnosed with SCC during this period. Median age at initial diagnosis was 52.0 (interquartile range: 46.0-61.8) years. The most common symptoms were bleeding (n = 93, 64.6%), noticing a lump (n = 49, 34.0%), and pain (n = 47, 32.6%). The proportion of patients at the American Joint Committee on Cancer (AJCC) stages I-IV were 10 (6.9%), 22 (15.3%), 61 (42.4%) and 8 (5.6%), respectively, and AJCC stages in 43 (29.9%) patients were unknown. Thirty-six patients (25.0%) underwent abdominoperineal resection initially. Univariable analysis showed that T stage predicted recurrence-free survival (RFS) (Hazard ratio [HR] = 3.03, 95% Confidence interval [CI]: 1.10-8.37, p = 0.032), and age group (HR = 2.90, 95% CI: 1.12-7.49, p = 0.028), AJCC stage (HR = 4.56, 95% CI: 1.02-20.35, p = 0.046), and N stage (HR = 3.05, 95% CI: 1.07-8.74, p = 0.038) predicted overall survival (OS).

conclusionsT stage was identified as prognostic factor of RFS, and age, AJCC stage, and N stage were identified as prognostic factors of OS. Improving symptom awareness and earlier presentation among patients potentially at risk for anal SCC should be encouraged. Familiarity with the standard treatment among health care providers in China should be further improved.

Indexed as

Anus NeoplasmsCarcinoma, Squamous CellAgedAge FactorsAntineoplastic Combined Chemotherapy ProtocolsChinaConfidence IntervalsDisease-Free SurvivalFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedNeoplasm StagingPrognosisRadiotherapy DosageAnal cancerChinaEpidemiologySquamous cell carcinomaTreatment

Identifiers

PMID32693779
PMCPMC7372759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.